Unlocking nature's potential for tomorrow's medicines
C4D connects scientific centres to discover promising natural compounds and strengthen the early pipeline for urgently needed anti-infectives
25+ scientific centres · 5 continents · LMIC participation
The world needs new anti-infectives. Discovery needs a new approach.
Antimicrobial resistance (AMR) is accelerating, infectious diseases continue to disproportionately impact low- and middle-income countries (LMICs), while the pipeline for new anti-infective medicines remains limited. At the same time, nature contains vast chemical diversity with potential for new medicines. C4D addresses the gap between this untapped potential and the early discovery of tomorrow's medicines.
Creating a platform for discovery that can be leveraged across borders, diseases and future programmes.
C4D is one global network sharing discovery capacity
• Discovering natural compounds with potential
• Connecting expertise, technology and infrastructure
• Advancing early-stage discovery pipelines for urgently needed anti-infectives
Why C4D is different
Global
• Expertise and infrastructure connected across geographies
Open
• Knowledge, technology and capabilities shared through open science
Equity
• Equitable benefit sharing and strengthening discovery capacity where disease burden is greatest with LMIC participation
Mission-Driven
• Focusing on the early discovery gap and urgent need for new anti-infectives
C4D connects global capability at the point where new medicines begin.
Help build the discovery engine for tomorrow's medicines
C4D is seeking strategic foundations and partners to accelerate discovery
“Anti-infective drug research has tended to be segregated and competitive. C4D’s ambition is to change the modus operandi, finding a new way of working together. Our coordinated effort is focusing on early-stage discovery of promising chemical entities, ultimately leading to clinical trials of medicines.”
Gilles Van Wezel, C4D Founder & Coordinator